Article
Salt Lake City, UT-Paradigm Medical announces that its optimism over news that prospects of the $70-million purchase order the company reported recently were not as solid as it had thought.
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Cost-effectiveness of AI pediatric eye screening
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT